Stockreport

CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026 [Yahoo! Finance]

CG Oncology, Inc.  (CGON) 
PDF CG Oncology logo Key Points BOND-003 Cohort C showed a 75.5% complete response rate "at any time" in 110 BCG-unresponsive CIS patients, a 12-month CR of 46.4%, and [Read more]